In this white paper, we will discuss the latest trends in digital biomarkers, their emerging applications and explore opportunities this creates for pharmaceutical companies. We will address key questions, such as: What determines the development path for digital biomarkers? What barriers need to be overcome for their widespread adoption? What new capabilities are required to seize the digital biomarker opportunity? And what role do technology partnerships play?